Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
Total Page:16
File Type:pdf, Size:1020Kb
Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh,* Sonia M. Leach,† Brandon L. Moore,* Tullia C. Bruno,* Jonathan D. Buhrman,* and Jill E. Slansky* Mechanisms of self-tolerance often result in CD8+ tumor-infiltrating lymphocytes (TIL) with a hypofunctional phenotype incapable of tumor clearance. Using a transplantable colon carcinoma model, we found that CD8+ T cells became tolerized in <24 h in an established tumor environment. To define the collective impact of pathways suppressing TIL function, we compared genome-wide mRNA expression of tumor-specific CD8+ T cells from the tumor and periphery. Notably, gene expression induced during TIL hypofunction more closely resembled self-tolerance than viral exhaustion. Differential gene expression was refined to identify a core set of genes that defined hypofunctional TIL; these data comprise the first molecular profile of tumor-specific TIL that are naturally responding and represent a polyclonal repertoire. The molecular profile of TIL was further dissected to determine the Downloaded from extent of overlap and distinction between pathways that collectively restrict T cell functions. As suggested by the molecular profile of TIL, protein expression of inhibitory receptor LAG-3 was differentially regulated throughout prolonged late-G1/early-S phase of the cell cycle. Our data may accelerate efficient identification of combination therapies to boost anti-tumor function of TIL specifically against tumor cells. The Journal of Immunology, 2016, 197: 1477–1488. http://www.jimmunol.org/ or some cancers, immunological data from tumor samples substantially altered by slight changes in the environment and Ag are better predictors of patient survival than those cur- encounter. In the context of cancer, tumor environments evolve to rently used to stage disease (1, 2). Compelling evidence suppress and evade CD8+ T cells (4); therefore, TIL typically have F + associates functional CD8 tumor-infiltrating lymphocytes (TIL) a hypofunctional phenotype incapable of mounting an effective with survival of patients with cancer. For example, patient survival attack against an established solid tumor (5). positively correlates with TIL that produce proinflammatory cy- Exhaustion, tolerance, anergy, senescence, and ignorance are tokines such as IFN-g, kill target cells, and progress through the states of CD8+ T cell hypofunction that have been tied to TIL (3). cell cycle. These data suggest that the immunological status of Of these programs, hypofunctional TIL are most commonly re- TIL is paramount for patient response. ferred to as exhausted or tolerant. T cell exhaustion occurs during by guest on September 25, 2021 To acquire cytotoxic functions, the Ag receptor on naive T cells prolonged inflammation and/or TCR exposure to an Ag, such as must be engaged in a proinflammatory environment (3). Cell- during a chronic viral infection. Peripheral T cell tolerance occurs intrinsic pathways are then initiated to drive T cell proliferation more quickly when Ag is presented in the absence of immunos- and differentiation to cytotoxic T cells that kill cells expressing timulatory signals to avoid self-reactivity and autoimmunity. + the associated Ag. CD8 T cell activation and differentiation are Unlike naive or memory CD8+ T cells that, upon TCR and co- stimulation, enter the cell cycle to undergo clonal expansion into functional effector T cells, a functional response by exhausted and † *University of Colorado School of Medicine, Aurora, CO 80045; and Center for self-tolerant CD8+ T cells is constrained. Genes, Environment and Health, National Jewish Health, Denver, CO 80206 The promise of promoting functional TIL to treat patients with Received for publication April 5, 2016. Accepted for publication June 9, 2016. cancer has been developing for decades to produce a recent ex- This work was supported by American Cancer Society Grant RSG-08-184-01-L1B, plosion of clinical successes (6). Such therapies include blockade National Institutes of Health Grants 5T32AI007405 and 5R25GM083333, and a generous donation from Richard and Donna Hammel. of receptors, such as programmed cell death-1 (PD-1) (7), that The sequences presented in this article have been submitted to the National Center inhibit TIL function. However, a therapy that targets just one in- for Biotechnology Information Gene Expression Omnibus under accession number hibitory pathway is often ineffective against established solid tu- GSE79858. mors. Cotherapies targeting multiple pathways inhibiting TIL Address correspondence and reprint requests to Dr. Jill E. Slansky, University of function have recently translated from mouse models to the clinic Colorado School of Medicine, 12800 East 19th Avenue, Mail Stop 8333, Aurora, CO 80045. E-mail address: [email protected] (8). For instance, dual blockade of T cell inhibitory receptors PD-1 The online version of this article contains supplemental material. and TIM-3 was first shown to augment clearance of the CT26 Abbreviations used in this article: 7-AAD, 7-aminoactinomycin D; CU-SOM, Uni- solid tumor model in mice (9) and is now in clinical trials (trial versity of Colorado School of Medicine; EdU, 5-ethynyl-2’-deoxyuridine; FDR, false registration ID: NCT02608268). discovery rate; FOM, figure of merit; GSEA, gene set enrichment analysis; IPA, The transplantable colon carcinoma CT26 (10) reflects both the ingenuity pathway analysis; KMC, K-means clustering; NES, normalized enrichment score; PCA, principal component analysis; PD-1, programmed cell death-1; SAM, infiltrating immune cells and pathways of immune suppression significance analysis of microarray; SpTV, AH1-specific CD8+ T cell from spleens found in many solid human tumors that are immunogenic (11, 12). in CT26 tumor-bearing mice; SpV, AH1-specific CD8+ T cell from spleens in non–tumor-bearing mice; TASPR, tumor Ag-specific polyclonal repertoire; TIL, As with many Ags being pursued in patients with cancer (13, 14), + CD8+ tumor-infiltrating lymphocyte; TILN, tumor-specific CD8+ T cell isolated the immunodominant CD8 T cell response against CT26 is di- from lymph node metastases; TILV, tumor-infiltrating lymphocyte from vaccinated rected against a tumor/self-antigen, GP70 , also known as tumor-bearing mice. 423–431 AH1 (15, 16). CT26 TIL exhibit an exhausted phenotype similar + Copyright Ó 2016 by The American Association of Immunologists, Inc. 0022-1767/16/$30.00 to CD8 T cells from patients with melanoma that bear TCRs www.jimmunol.org/cgi/doi/10.4049/jimmunol.1600589 1478 MOLECULAR PROFILE OF TIL specific for a tumor/self-antigen (9, 17). The majority of CT26 When indicated, Ficoll-Paque PLUS (GE Healthcare) was used accord- TIL express multiple inhibitory receptors and are hypofunctional ing to the manufacturer’s instructions to enrich for live lymphocytes. (9). Nevertheless, mobilizing a functional CD8+ T cell response is Splenocytes were harvested from mice, mechanically dissociated, treated for ∼2 min with ammonium chloride-potassium lysis buffer (ACK) (22), necessary for successful anti-CT26 immunotherapy (18). filtered through a 100-mm cell strainer, and washed in complete medium. In this study, we show within just 24 h of transfer into a CT26 Before FACS, spleens were processed into single-cell suspensions through tumor-bearing host, AH1-specific CD8+ T cells that were pro- Liberase digestion, as performed for tumors. Before FACS and adoptive + tective in a prophylactic setting (19) were markedly hypofunc- transfer experiments, CD8 T cells were enriched from splenocytes using the Mouse CD8 Negative Selection Kit (Invitrogen) according to the tional in the tumor compared with those in the periphery. To manufacturer’s instructions. Cells were used directly for staining, in vitro molecularly define the collective impact of pathways that suppress stimulation assays, or adoptive cell transfer. AH1-specific TIL function,